stockrow
Friday 6 November 2026
Export GDTC’s income statement to Excel — free account
CytoMed Therapeutics Limited
GDTC Healthcare Biotechnology
CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024.
0.85
0.04
−4.49%
Follow GDTC
Alert me
CytoMed Therapeutics Limited (GDTC) P/E ratio
CytoMed Therapeutics Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| GDTC CytoMed Therapeutics Limited | n/m |
| AZR Azora Therapeutics, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. compare | 0.8× |
| PTN Palatin Technologies, Inc. compare | 12.2× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)